NORVIR
HIV Wasting Syndrome
Floatz Rating
D30/100
Confidence
Indicative
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Modality
Small molecule
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00028314CT.gov Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · HIV Wasting Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| NORVIR (this asset) | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | D · 30 |
| 2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)- | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P4 | BB |
| Serostim | EMD Serono | P3 | B |
| Megestrol Acetate | Endo USA Inc., a Keenova Therapeutics Company | P2 | B |
| Testosterone Undecylate | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P2 | B |
| Atazanavir | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | D |
| Lopinavir | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | D |
| Nevirapine Anhydrous | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | D |
| Abacavir | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | D |
Other indications for NORVIR
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Hepatitis C Virus Infection | — | P3 | BBB · 76 |
| Hepatitis C Virus Infection | — | P3 | BBB · 76 |
| HIV Infectious Disease | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- 2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)BB
- SerostimEMD SeronoB
- Megestrol AcetateEndo USA Inc., a Keenova Therapeutics CompanyB
- Testosterone UndecylateNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)B
- AtazanavirNational Institute of Allergy and Infectious Diseases (NIAID)D
Citation
Floatz Terminal. NORVIR in HIV Wasting Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/norvir-hiv-wasting-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →